Published in Iran Red Crescent Med J on February 01, 2011
Regulators of gene expression as biomarkers for prostate cancer. Am J Cancer Res (2012) 0.98
Adipocyte secreted factors enhance aggressiveness of prostate carcinoma cells. PLoS One (2015) 0.77
Loss of heterozygosity for chromosomal regions 15q14-21.1, 17q21.31, and 13q12.3-13.1 and its relevance for prostate cancer. Med Oncol (2015) 0.75
The future of genetic studies of complex human diseases. Science (1996) 64.76
Translating the histone code. Science (2001) 56.77
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nat Genet (1999) 25.93
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007) 14.37
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev (2010) 12.60
Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature (1994) 8.04
A DNA polymorphism discovery resource for research on human genetic variation. Genome Res (1998) 7.44
Global histone modification patterns predict risk of prostate cancer recurrence. Nature (2005) 7.03
Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev (2004) 6.19
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene (2007) 5.79
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst (2000) 5.21
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
DNA methylation and cancer. J Clin Oncol (2004) 4.58
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer (2004) 4.10
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun (1990) 3.79
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst (2003) 3.73
The ISWI chromatin-remodeling protein is required for gene expression and the maintenance of higher order chromatin structure in vivo. Mol Cell (2000) 3.62
Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res (1999) 3.41
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24
Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev (2008) 3.05
Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst (2008) 3.04
Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet (1998) 2.90
An ACF1-ISWI chromatin-remodeling complex is required for DNA replication through heterochromatin. Nat Genet (2002) 2.87
TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res (2006) 2.82
Multiple prostate cancer risk variants on 8q24. Nat Genet (2007) 2.76
Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst (1997) 2.74
Mismatch repair, genetic stability, and cancer. Science (1994) 2.65
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer (2007) 2.62
Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate (2004) 2.49
Preferential response of cancer cells to zebularine. Cancer Cell (2004) 2.39
Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res (2005) 2.37
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res (1994) 2.34
The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat (2004) 2.25
Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J Pathol (2007) 2.17
Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res (2002) 2.09
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol (2005) 2.05
Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst (2005) 2.03
Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem (1995) 2.02
Abnormal patterns of DNA methylation in human neoplasia: potential consequences for tumor progression. Cancer Cells (1991) 1.95
A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. J Urol (2006) 1.86
Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol (2005) 1.80
Dietary selenium and arsenic affect DNA methylation in vitro in Caco-2 cells and in vivo in rat liver and colon. J Nutr (2000) 1.71
A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res (2000) 1.70
Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst (2006) 1.70
Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev (2002) 1.60
SNP alleles in human disease and evolution. J Hum Genet (2002) 1.59
Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. Int J Cancer (2002) 1.58
Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene (2003) 1.56
Relationship of folate, vitamin B-6, vitamin B-12, and methionine intake to incidence of colorectal cancers. Nutr Cancer (2002) 1.55
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res (2001) 1.49
DNA methyltransferase inhibitors-state of the art. Ann Oncol (2002) 1.43
Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol (2004) 1.40
Phenotypic heterogeneity of mutations in androgen receptor gene. Asian J Androl (2007) 1.36
Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene (2005) 1.33
Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin Cancer Res (2001) 1.33
Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun (2001) 1.30
Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res (2005) 1.30
Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res (1987) 1.30
p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res (2002) 1.29
Androgen receptor signaling and mutations in prostate cancer. Asian J Androl (2010) 1.27
Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst (2002) 1.24
Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate (2001) 1.23
Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol (2009) 1.23
Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res (1996) 1.23
Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab (1996) 1.22
Hepatocarcinogenesis in rats fed methyl-deficient, amino acid-defined diets. Carcinogenesis (1983) 1.22
Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res (2005) 1.22
Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res (1998) 1.21
ATP-dependent chromatin remodeling activities. Cell Mol Life Sci (2001) 1.15
Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res (1996) 1.14
Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin Cancer Res (1995) 1.13
The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men's Health Study. J Hum Genet (2008) 1.10
Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling. PLoS One (2010) 1.09
Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol (2004) 1.08
Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine (2006) 1.07
DNA methylation in prostate cancer. Biochim Biophys Acta (2004) 1.07
Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosomes Cancer (1996) 1.03
Chemopreventive effects of tea extracts and various components on human pancreatic and prostate tumor cells in vitro. Nutr Cancer (1999) 1.01
Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer (2008) 1.01
Molecular markers for predicting prostate cancer stage and survival. BJU Int (2000) 1.01
Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep (2004) 1.01
Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate (2004) 1.00
A loss of insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor down-regulation at senescence in human epithelial cells. J Biol Chem (2004) 1.00
Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res (2005) 0.99
ICAM gene cluster SNPs and prostate cancer risk in African Americans. Hum Genet (2006) 0.99
A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori (1998) 0.99